How to Report PSMA PET – Beyond the Abstract
methods to convey PSMA-PET/CT results, prostate cancer, Prostate-Specific Membrane Antigen (PSMA), PSMA PET, 177Lu-PSMA-SPECT, biochemical recurrence (BCR), PROMISE, PRIMARY, PSMA_RADS, E-PSMA.
methods to convey PSMA-PET/CT results, prostate cancer, Prostate-Specific Membrane Antigen (PSMA), PSMA PET, 177Lu-PSMA-SPECT, biochemical recurrence (BCR), PROMISE, PRIMARY, PSMA_RADS, E-PSMA.
AUA 2024, N-803 plus BCG, Non Muscle Invasive Bladder Cancer (NMIBC), BCG Refractory, QUILT 3032 trial, ANKTIVA, interleukin-15 superagonist (IL-15), BCG-unresponsive high-grade NMIBC.
AUA 2024, non-muscle invasive bladder cancer (NMIBC), trans urethral resection of bladder tumor (TURBT), HG T1 bladder cancer, Replacing ReTUR with Cystoscopy, HuNIRe trial, urine cytology,…
AUA 2024 efficacy of repeat BCG challenge in patients with “BCG unresponsive” non-muscle invasive bladder cancer (NMIBC), BCG-unresponsive NMIBC,
AUA 2024 advanced prostate cancer, molecular imaging (mi) node positive disease (miN1) undergoing radical prostatectomy, extended pelvic lymph node dissection (ePLND).
Andrea Apolo joins Sam Chang in discussing the AMBASSADOR study, focusing on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma. The study showed improved disease-free survival with…
AUA 2024 third interim analysis of the DARolutamide ObservationaL (DAROL) study, nonmetastatic castration-resistant prostate cancer (nmCRPC), DAROL study, darolutamide, phase 3 ARAMIS trial.
AUA 2024, muscle-invasive bladder cancer (MIBC), depression in muscle-invasive bladder cancer patients, neoadjuvant chemotherapy (NAC), Effects of Neoadjuvant Chemotherapy on Rates of Depression.
Technological advancements, evolving patient expectations, and global health challenges reshape how healthcare professionals deliver care.
renal mass, renal cell carcinoma (RCC), kidney cancer, Partial Nephrectomy (PN), Radical Nephrectomy (RN), renal mass in a solitary kidney (RMSK), chronic kidney disease (CKD),…
AUA 2024 results of a phase 1 dose-escalation trial of multiple and fractionated-dose PSMA-targeted alpha radionuclide 225Ac-J591, metastatic castration-resistant prostate cancer (mCRPC), advanced prostate cancer.